The ticker symbol PLX represents the common stock of Protalix BioTherapeutics, Inc., traded publicly on the NYSE American stock exchange. Holding these shares provides investors with equity exposure to the clinical-stage biopharmaceutical sector, specifically capturing financial performance tied to its proprietary plant-expressed recombinant protein platform and commercial rare disease drug portfolio.